Within the pharmaceutical industry it has become more and more apparent that the cost for the development of new products increases while the number of products that reaches the market declines. One of the causes for this phenomenon is the limited sensitivity of existing lung function tests to detect changes in pulmonary function in an early stage. Therefore within the field of respiratory medicine a consensus is starting to form around the need for new outcome parameters.